Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 8/20 | 0.47 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 4/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490458 | 0.91 | ANO1 (0.55) | ANO1ANO2PYGLGRM4 | |
| SCHEMBL12831284 | 0.89 | ANO1 (0.56) | ANO1NPC1RAB9A | |
| SCHEMBL12756881 | 0.88 | PPARG (0.49) | ANO1KMT2ANPC1RAB9A | |
| SCHEMBL12830932 | 0.88 | ANO1 (0.43) | ANO1ANO2KMT2ANPC1RAB9A | |
| SCHEMBL1490673 | 0.86 | ANO1 (0.45) | ANO1ANO2KMT2AKDM4ENPC1 | |
| SCHEMBL12831006 | 0.84 | MEN1 (0.53) | ANO1KMT2ARAB9AHPGD | |
| SCHEMBL1490568 | 0.82 | MEN1 (0.49) | KMT2ANPC1GLARAB9AHPGD | |
| SCHEMBL3630195 | 0.81 | ANO1 (0.71) | ANO1ANO2KMT2ANPC1RAB9A | |
| SCHEMBL12756890 | 0.81 | PPARG (0.56) | ANO1KMT2ANPC1RAB9A | |
| SCHEMBL1490367 | 0.81 | MEN1 (0.50) | KMT2AKDM4ENPC1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2477982-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ANO2 98/4885PYGL 1403/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ANO2 98/4885PYGL 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.